Coya Therapeutics, Inc.’s Post

#Primary_Cells Market Share Expected Huge Growth during 2023-2032 https://lnkd.in/dmXKXJke The rise in the prevalence of cancer cases will drive the growth of the primary cell #market. The increase in the #biopharmaceutical and #biotechnology sector for medical research is anticipated to foster the market expansion of the primary cell. Using patient-derived samples in advanced #preclinical #technologies, like #3D cell #cultures, which produce accurate results, boosts the market #growth of #primary #cells. Thermo Fisher Scientific Lonza Cell Biologics, Inc PromoCell ZenBio STEMCELL Technologies AllCells ATCC-American-Type-Culture-Collection Axol Bioscience Ltd. #Primary_Cells #healthcare #business_opportunities #marketanalysis #marketresearch #opportunities #business #future #primary #cells

#Primary_Cells Market Share Expected Huge Growth during 2023-2032 https://lnkd.in/dmXKXJke PromoCell Nucleome Therapeutics Lifeline Cell Technology RAMCON ImmunXperts, a Q² Solutions Company Primera Analytical Solutions Corporation Preferred Cell Systems™ Celprogen, Inc HCS Pharma ReachBio Research Labs Phasefocus Scintillant Bioscience Biopredic International StressMarq Biosciences Inc. BioNordika Denmark A/S Worthington Biochemical Corporation BioPharmaSpec Saguaro Technologies Bio Elpida Fluofarma ATLANTIC BONE SCREEN TargImmune Therapeutics AG Essent Biologics BioNordika Sweden AB Vitro Biopharma, Inc. LGC in partnership with ATCC Neuromics VITARIS AG Abalos Therapeutics GmbH CNS Pharmaceuticals, Inc. Evercyte GmbH Novabiosis, Inc. ION Biosciences Bioseek Innoprot ZenBio PELOBIOTECH GmbH SV Biotech BV Basilard BioTech, Inc. Cellanyx #Primary_Cells #healthcare #business_opportunities #marketanalysis #marketresearch #opportunities #business #future #primary #cells

Looking to reduce your #therapeuticprograms timeline ? Leap forward in your therapeutic programs with 5500+ functional & binding #cellbasedassays used to interrogate billions of data points across discovery into development through #commercialrelease & stability programs. With 25+ years of expertise in cell line engineering, assay design, method qualification, & production, product solutions from Eurofins DiscoverX® enables acceleration of multi-modality therapeutics programs by reducing development times by 6 to 9 months. Discover More…  https://lnkd.in/g7ek6dDh #drugdevelopment

Examining the clinical use of engineered exosomes for therapeutic protein delivery: in this concise review, Chulhee Choi at ILIAS Biologics Inc. and collaborators discussed the challenges in developing exosomes as drug carriers and provided insights into strategies for their effective clinical translation https://lnkd.in/gTmHpiDe Additionally, they highlighted preclinical studies that have successfully used anti-inflammatory exosomes and suggested future directions for exosome therapeutics. An article also authored by Minseong Kim, Hojun Choi, Deok-Jin Jang, Hye-Jung Kim, Yujin Sub and Heon Yung Gee #extracellularvesicles #exosomes #bioengineering #drugdelivery #therapeutics #Vesiculab

📢  Pfizer has announced the discontinuation of OXBRYTA for Sickle Cell Disease (SCD) in all approved markets after data indicated a higher risk of vaso-occlusive crises and fatal events, which they consider outweigh the benefits of the treatment. ❗️This comes as a major blow for the company after having acquired the originator, Global Blood Therapeutics, for $5.4B in 2022. Regardless, Pfizer will push ahead with its other SCD candidates. ➡️ This decision may also serve as a potential catalyst for CRISPR Therapeutics and Vertex Pharmaceuticals' CASGEVY, the first approved Cas9 gene-edited therapy for SCD. 🌟 The future of SCD treatment is evolving rapidly, and gene-editing therapies could represent a significant advancement in early detection and management. #SickleCellDisease #GeneTherapy #CRISPR #Pfizer #Biotech

Thoughts on this? >> Australian RNA manufacturer launches; Forge Biologics’ CEO steps down >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #biotech #healthcare #pharmaceutical #pharma #productmarketing

#Clinical_Stage_Biotechnology Market Share Charges Ahead with Huge Growth 2023-2032 https://lnkd.in/dtEG_mxy #Clinical stage biotechnology refers to a #phase in the development of biotechnological #products, particularly #therapeutic drugs or interventions, where the focus #shifts from preclinical #research and testing to human clinical #trials. These are designed to assess the #safety, efficacy, and optimal #dosage of the biotechnological #product in humans. Minoryx Therapeutics Inhibrx, Inc. NovaBiotics Ltd Radiomedix, Inc. Artax Biopharma Inc Ribon Therapeutics Brickell Travel Management Coave Therapeutics Edesa Biotech, Inc. CellCentric LimmaTech Biologics AG Adaptive Phage Therapeutics Intrainz #technologies #marketgrowth #innovationmanagement #clinical #biotechnology #therapeutic #drugs #research

The development of custom peptides and oligonucleotides has opened new horizons for targeted #therapeutic interventions. However, the success of #peptide and #oligonucleotide development hinges significantly on a comprehensive understanding of their stability. The good news is that #biopharma teams using ARGEN can access real-time stability insights as they develop peptide, oligonucleotide, and #protein based therapeutics. Click here to learn more. https://lnkd.in/gEqQKNDK

Yihan L., a Senior Scientist at AbbVie, walks us through her teams latest poster: "A Novel in vitro Serum Stability Assay for Antibody Therapeutics Incorporating Internal Standards." Yihan explains her team's innovative approach to pre-animal testing screening for biologics, focusing on stable molecule identification through precise incubation and LC-MS analysis. Discover how the use of internal standards, including NISTmAb and its Fc fragment, improve data accuracy and quality - promising findings that could transform biologics screening! https://bit.ly/3z7B1oK Rosendo Villafuerte-Vega, Hetal Sarvaiya #massspectrometry #glycosylation #oligonucleotides #vaccines #biotherapeutics #proteomics Dotmatics #biosimilars #cdmo

Are you joining the Conversation on Multispecific Therapeutics?🔬🚀 Don't miss out on the roundtable discussion, "Challenges Facing the Development and Production of Multispecific Therapeutics," on 18 Nov 2024, from 17:05 - 18:05 at the Antibody Therapeutics Xchange - Brussels! 👥 Secure your spot now and be part of this essential discussion! 📝 https://lnkd.in/eQ9rs5u5 🧬 Key Discussion Points: 🧪 Do complex sequences impact titer, assembly, and purification? 🧬 Off-target effects vs. target affinity, specificity, and patient safety — what's the balance? 🧫 Are standard analytics platforms sufficient for complex molecule formats? 🔬 How do you adapt functional assays for multiple target modes of action? 🧪 Phase-specific approaches for complex mechanisms and functional assay timing. Featuring Sabrina Vollers, PhD, Director, Head of Drug Product and Analytical Development - Ichnos Glenmark Innovation who will share her expertise in bi- and multispecific antibody therapeutics. 🧑🔬 Only available for Senior Scientists and above, from Bio and Pharma companies, with a drug pipeline. 💊 #BiSpecifics #Multispecifics #AntibodyTherapeutics #PharmaInnovation #DrugDevelopment #Biotech #Immunotherapy #AnalyticalDevelopment #Xchange #PharmaScience #RND #ScientificRoundtable #hubXchange #Xchanges #Roundtable #FreePass #RegisterNow #ComplimentaryPass